A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.
Earlier this month, the US Food and Drug Administration (FDA) approved the expanded use of Edwards SAPIEN 3 transcatheter aortic valve replacement (TAVR) to include the treatment of severe, symptomatic aortic stenosis in patients at low risk of open-heart surgery.
The indication made the innovative cardiovascular procedure possible for high-risk and low-risk surgery patients—and brought further discussion to what the future of invasive versus non-invasive care looks like in US patients.
This week’s #DocTalk is untapping the potential of TAVR, with the help of a leading expert on the procedure.
#DocTalk is a weekly conversation featured on Twitter that focuses on the biggest issues in healthcare today. Join us on Wednesday, August 28 at 12 PM EST for the start of our chat, featuring Michael Mack, MD, FACC, Chair of the Cardiovascular Governance Council, Medical Director of Cardiovascular Surgery at Baylor Scott & White (BSW) The Heart Hospital — Plano, and Medical Director of the Cardiovascular Service Line, at BSW.
Mack, the co-primary investigator of the Placement of Aortic Transcatheter Valves (PARTNER) 3 Trial, will be leading discussion from the BSW twitter account (@bswhealth) on the following questions:
We invite all interested Twitter users to participate in the chat and contribute their own perspective and questions.
Be sure to search for “#DocTalk,” follow MD Mag on Twitter (@MDMagazine), and look for the social media icon signifying the chat:
If you’re a frequent Twitter user with a background in healthcare and interest in leading a #DocTalk chat with your colleagues, contact us here.